Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (2.381%)
Market Cap: £81.54m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Market Update

15 Jan 2018 07:00

RNS Number : 8401B
Iofina PLC
15 January 2018
 

 

15 January 2018

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Market Update

 

2017 iodine production target exceeded

Iodine prices rise during 2017

New plant online imminently

 

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, is pleased to update the market on its 2017 iodine production totals, general progress and iodine production outlook for H1 2018.

 

Highlights:

· H2 2017 crystalline iodine production was 267.5 Metric Tonnes ("MT"), an increase of 22% (H2 2016: 216.6MT), exceeding upward revised targets

· 2017 total crystalline iodine production was 503MT, an increase of 6% (FY 2016: 474.2MT) despite plant IO#3 being offline for three quarters of 2017 for repurposing

· Iodine prices increased further in H2 2017 to $24/kg (H2 2016: $20/kg), and continue to edge upwards

· New plant IO#7 nearly complete and will significantly increase production

· IO#5 plant being reviewed for potential reconfiguration to improve profitability

· Iofina Chemical continues to trade strongly in both iodine and non-iodine products

· H1 2018 production currently forecast at 300-340MT

 

During H2 2017, Iofina produced 267.5MT of crystalline iodine from its four operating IOsorb® plants located in the state of Oklahoma USA, a 22% increase from H2 2016. For the year the Group produced 503MT of crystalline iodine, a 28.8MT increase versus 2016 despite operating with one less plant for approximately three quarters of 2017. This output slightly exceeded the upward revised targets published by Iofina in December 2017. 

 

Global Iodine prices in H2 2017 moved higher to approximately $24/kg for large orders. This represents a significant increase as iodine prices in late 2016 were at or below $20/kg. Moving into early 2018, iodine prices have continued to move slightly higher and the Board expects iodine prices to continue to rise this year, as current iodine prices remain below historical levels and some Chilean iodine production has been reduced in 2017. As an iodine producer and iodine derivative manufacturer, the Group is poised to benefit from any increase in the sales price of iodine.

 

The construction of the new IO#7 plant, which is utilizing much of the assets of IO#3, remains on track to begin production in early February. The construction of IO#7 has progressed on time and within budget and is a testament to the accumulated skill, experience and planning capability that now resides in our construction and operations teams. Once IO#7 is commissioned, the Group's daily iodine run-rate will significantly increase and the overall per unit iodine production costs in 2018 will be lower than in 2017. The Group's goal of being a lower quartile cost iodine producer remains a key focus throughout 2018.

 

A new image of the IO#7 construction progress can be viewed on the Company's website www.iofina.com or by clicking the link below:

http://www.rns-pdf.londonstockexchange.com/rns/8401B_-2018-1-15.pdf

As Iofina continues to execute plans to increase production with greater efficiencies at reduced costs, the Company continues to investigate options to upgrade our iodine production portfolio. To that end, Iofina is exploring options for IO#5, which is currently the Group's highest production cost plant. In conjunction with our brine supply partner, we are modelling various scenarios and currently executing field trials to move brine from IO#5 to other IOsorb® plants, potentially increasing production at those plants while reducing our overall production cost. The Group is exploring a new additional brine water source at its IO#5 location or repurposing the plant to another site. We will update the market once we have concluded our field trials and optimised our 2018 plans. These initiatives continue the Group's long-term goal of increasing production, while reducing our net production costs. Other operational improvements at our IOsorb® plants are planned in 2018.

 

Iofina Chemical performed strongly in H2 2017 as sales of both iodine and non-iodine halogen based compounds achieved consistently good results and outperformed internal H2 2017 projections. Iofina Chemical continues to globally provide high quality products to the Company's longstanding and new customers, and has developed and sold new products within our core competency in 2017. 

 

The Directors believe the Company will produce between 300-340MT of crystalline iodine in H1 2018. Iofina will provide additional guidance on our iodine production, likely in Q2 2018, as operations become more normalized once IO#7 comes on-line and has operated for a period of time.

 

Commenting, President and CEO Dr. Tom Becker, stated: ''The Board is encouraged by the excellent operational performance achieved in 2017 and the direction in which the Company is heading. We successfully executed efficiency improvements at current facilities, which have resulted in the Group exceeding 2017 production targets.

 

"As we enter 2018, we are continuing to strategically expand iodine production by bringing IO#7 into production, a plant which will significantly increase iodine output whilst reducing the Group's overall iodine production cost. Iofina Chemical continues to expertly deliver high quality new and existing, niche products to the global market.

 

"The outlook for 2018 is positive, and the Group will explore additional scenarios to improve its production costs and increase output. The accomplishments achieved last year by our highly skilled workforce, coupled with the recent increasing iodine prices, position Iofina for continued growth and success this year and beyond.

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Emily Morris

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDSFSSMIFASEIF
Date   Source Headline
15th May 20204:35 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSPPP Loan Received
4th May 20207:00 amRNSIO#8 Brine Supply Update
14th Apr 20207:00 amRNSQ1 Market Update
2nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20201:53 pmRNSWithdrawal of requisition for General Meeting
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
17th Mar 20204:41 pmRNSSecond Price Monitoring Extn
17th Mar 20204:35 pmRNSPrice Monitoring Extension
16th Mar 202012:07 pmRNSSecond Price Monitoring Extn
16th Mar 202012:02 pmRNSPrice Monitoring Extension
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20201:56 pmRNSClarification Regarding Media Reports
11th Mar 202012:08 pmRNSSecond Price Monitoring Extn
11th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20207:30 amRNSBoard response to recent GM request
10th Mar 20207:00 amRNSRequisition of General Meeting
3rd Mar 20207:10 amRNSStatement re: press and social media reports
2nd Mar 202012:22 pmRNSHolding(s) in Company
25th Feb 202012:00 pmRNSMarket Update
10th Feb 20205:15 pmRNSHolding(s) in Company
10th Feb 20205:15 pmRNSHolding(s) in Company
16th Jan 20207:00 amRNSMarket Update - Strong H2 2019
2nd Jan 202011:11 amRNSHolding(s) in Company
20th Dec 20197:00 amRNSTrading Update
14th Nov 20193:51 pmRNSHolding(s) in Company
14th Nov 20193:50 pmRNSHolding(s) in Company
12th Nov 20191:43 pmRNSHolding(s) in Company
6th Nov 20197:00 amRNSIofinaEX Hemp Seed Investment
14th Oct 20197:00 amRNSQ3 2019 Update
26th Sep 201910:00 amRNSHolding(s) in Company
25th Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSInterim Results
18th Sep 20197:00 amRNSTerms for IO#8 Finalised - Construction Commences
29th Aug 20194:41 pmRNSSecond Price Monitoring Extn
29th Aug 20194:35 pmRNSPrice Monitoring Extension
13th Aug 20197:00 amRNSIncorporation of IofinaEX Global
29th Jul 20197:00 amRNSGrant of Share Options
24th Jul 20193:08 pmRNSHolding(s) in Company
16th Jul 20192:17 pmRNSHolding(s) in Company
12th Jul 20197:00 amRNSH1 2019 Update
17th Jun 20191:49 pmRNSHolding(s) in Company
17th Jun 201910:55 amRNSHolding(s) in Company
17th Jun 201910:53 amRNSHolding(s) in Company
13th Jun 201912:00 pmRNSResult of AGM and Open Offer
13th Jun 20197:00 amRNSIofinaEX Application Conditionally Approved
20th May 20197:00 amRNSProposed Placing and Open Offer
14th May 20197:00 amRNSStatement regarding share price rise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.